Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer

By K. Fizazi, N. Tran, L. Fein, N. Matsubara, A. Rodríguez‐Antolín, B. Alekseev, M. Özgüroğlu, D. Ye, S. Feyerabend, A. Protheroe and 5 more. New England Journal of Medicine, 2017

1,951 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/dde5a258d8e712a9997802512ee3cc7a4a53f071

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. N. Mottet
2. M. Hallek
3. R. DePinho
4. Thomas Wiegel

In Pulmonary and Respiratory Medicine

1. M. Hallek
2. N. Mottet
3. Thomas Wiegel

Citations in the corpus

• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, background): “STAMPEDE arm G [186] LATITUDE [57] ENZAMET [78] TITAN [77]”
• Prostate Cancer (2018, background): “At a minimum, bladder scan and flow rate characteristics coupled with cystoscopy provide data to guide the decision for downsizing [6, 7].”
• Genetics and biology of prostate cancer (2018, background): “Abiraterone, a CYP17A1 inhibitor that blocks androgen production, also improves survival of patients with advanced prostate cancer with or without prior chemotherapy (de Bono et al. 2011; Ryan et al. 2013; Fizazi et al. 2017; James et al. 2017).”
• ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer (2019, background): “Two recent studies that investigated abiraterone in addition to ADT excluded men with prior docetaxel chemotherapy and did not include prospective evaluation of results by disease volume (high v low).(10,11) ARCHES (ClinicalTrials.”
• Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. (2018, background): “001 [both in favor of the abiraterone plus ADT arm in the STAMPEDE trial]).(5,6) Notably, the predominant population accrued to these studies had de novo metastatic disease.”